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Breast Cancer Gene Isolated
A team ofresearchers at the NIEHS, in col-
laboration with researchers at the University
of Utah Medical Center, have isolated
BRCAJ, a gene that plays a major role,4
inherited breast cancer and ovarian
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It has been known for years that the
mutant form of BRCAJ, which is located
on human chromosome 17, predisposes
women to breast and ovarian cancers.
However, the NIEHS and University of
Utah researchers are the first to pinpoint
the exact location ofBRC41 and clone it in
the laboratory. Using a technique known
as positional cloning, the researchers creat-
ed a detailed map of 17q, the area of the
chromosome that contains the breast can-
cer gene. They then focused on genes in
that area expressed in normal breast tissue
and compared them with mutational dam-
age in tissue from women known to carry
the defective form ofBRCAJ.
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Gene team. NIEHS Director Kenneth Olden (left) with senior members ofthe NIEHS team that identified the
breast cancersusceptibility gene (leftto right): J. Carl Barrett, RogerW.Wiseman, and Andrew Futreal.
recently been mapped to chromosome 13,
has not yet been isolated. However,
BRCA2, unlike BRCA1, is not implicated
an cancer.
eased risk for breast cancer has
Mbserved in families with Li-
syndrome, which is linked to
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c4I?B1 gene.
Althouh the isolation of BRCAJ has
n;ii;iSnw4iate iiplications for breast can-
cer screenng and treatment in the general
p atii isignificantly advances the
lng4term goal of research to mitigate
gtic dTSilefects. Existing tests for the muta-
are used only in individuals from fam-
il0es known to carry the defective gene.
Isolaton of the gene may lead to develop-
ment of tests for the gene itself rather than
based on genetic markers. Such a test
*Wd have to be able to identify a variety
bfmutations spread widely across the gene.
Untdl BRCAJ is better understood, testing
for mutations will be limited to research to
learn more about the gene.
The introduction of genetic testing
into mainstream medical practice has been
a major priority issue for the Ethical, Legal,
Ind Social Implications program of the
Human Genome Project. In addition, a
task force on genetic testing is being set up
by the Department ofHealth and Human
Services to consider these issues. The task
force will include consumers, geneticists,
government officials, and biotechnologists.
In the meantime, a woman with a fam-
ily history ofbreast cancer, especially ifthe
cancers were diagnosed at a young age,
should discuss early detection procedures
for breast cancer with her doctor.
NIEHS Launches
Clearinghouse
Where do people go when they have ques-
tions about environmental health and
related issues? Beginning October 1994,
the National Institute of Environmental
Health Sciences in Research Triangle Park,
NC, will provide a major, national infor-
mation source and referral point for ques-
tions about health and the environment
with the establishment ofEnviroHealth, an
environmental health information clearing-
house, accessible toll-free through 1-800-
NIEHS94 (643-4794).
Kenneth Olden, NIEHS director, has
given the clearinghouse top priority and
822 Environmental Health Perspectives-
asked his staff to analyze the gaps in the
availability of environmental health sci-
ences information to the public and devel-
oping a plan for implementing the clear-
inghouse. "The excellent science done at
NIEHS is at the heart ofour mission, but
unless information from our laboratories
and our scientists is accessible to a wider
public, NIEHS cannot fulfill its mission,"
Olden said. "The clearinghouse will reach
out to environmental journalists, environ-
mental justice organizations, educators,
and other target audiences. The public's
requests for information and public com-
ments received by the clearinghouse will
better enable the institute to respond to
the needs ofthe American people."
When appropriate, the clearinghouse
will provide written material describing
NIEHS research and training programs,
and callers will be referred to other clear-
inghouses, toll-free numbers, federal, state,
and local agencies, and information
sources as needed. Full use will be made of
various computer networks and the devel-
oping information superhighway to make
information readily available to the public.
The Office of Planning and Commun-
ications at the NIEHS has worked closely
with Information Ventures, Inc., a
Philadelphia-based contractor, to bring the
Clearinghouse on-line.
Daniel VanderMeer, director of the
NIEHS Office ofPlanning and Commun-
ications, has been the NIEHS project offi-
cer for the clearinghouse since the begin-
ningplanning stages. "The clearinghouse is
designed to expand the lines of communi-
cations with other institute programs, our
university-based centers across the U.S.,
the NIEHS Division of Intramural Re-
search, and the National Toxicology
Program, for example, to ensure the best
possible information on a broad range of
issues," VanderMeer said. "A central part
ofour effort will be to develop communi-
cations objectives for the institute and the
clearinghouse that are specific, attainable,
prioritized, measurable, and time specific."
NTP Announces Bioassay
Results
The National Toxicology Program presented
six more technical reports in its ongoing series
oftoxicology and carcinogenesis studies. All
six reports wereapproved bytheNTP's Board
of Scientific Counselors' Technical Reports
Subcommittee in apublic reviewheldJune21
at the NIEHS. Each report involves aseries of
long-term studies in which male and female
rats or micewere given a range ofdoses oftest
chemical followed by extensive histopatholog-
iCexaminlation.
* 1-trans-delta-9-tetrahydrocannabinol
(THC), the psychoactive ingredient in
Money for minority health. John Ruffin (left) director of the Office of Research on Minority Health, and
Kenneth Olden, director ofthe NIEHS.
marijuana, gave no evidence of carcino-
genic activity in male or female rats given
daily doses ofup to 50 milligrams per kilo-
gram body weight for 2 years. In male and
female mice, the evidence ofcarcinogenici-
ty was considered equivocal, based on
increased incidences of thyroid gland
tumors in animals receiving 125 mil-
ligrams per kilogram bodyweight.
* Acetonitrile, a polar solvent used pri-
marily to extract fatty acids and animal
and vegetable oils and for distillation of
pharmaceutical products including vita-
mins and steroids, was tested by inhalation
in groups ofmale and female rats and mice
in a series of 13-week and 2-year studies.
There was equivocal evidence of carcino-
genic activity in male rats based on a slight
increase in the incidence ofliver neoplasms
and no evidence ofcarcinogenic activity in
female rats or in male or female mice.
* Benzethonium chloride, used primar-
ily in cosmetics as a cationic surfactant and
an antimicrobial, was tested by dermal
application to the backs of male and
female rats and mice. Although this regi-
men resulted in development of epithelial
hyperplasia in rats and mice, there was no
evidence of carcinogenic activity in either
species.
* t-Butyl alcohol has a variety of
industrial uses, particularly in perfumes
and aerosol sprays and in cosmetics, with
annual production in the U.S. nearing
three billion pounds. This chemical was
administered in drinking water to rats
and mice for two years. Male rats exhibit-
ed some evidence ofcarcinogenic activity
based on increased incidences of kidney
neoplasms, but there was no evidence of
carcinogenicity in female rats. Male mice
had a marginal increase in thyroid gland
tumors, which was judged equivocal evi-
dence of carcinogenic activity, while in
female rats the increase in thyroid gland
tumors was more pronounced and consti-
tuted some evidence of carcinogenic
activity.
* l-Amino-2,4-dibromoanthraquinone
is one of a series of five substituted
anthraquninone dyes that have been stud-
ied by the NTP. When given in the feed,
this chemical induced large numbers of
neoplasms in a variety oftissues, including
the liver, intestine, kidney, and urinary
bladder in rats and the liver, forestomach,
and lung in mice, and was judged to
exhibit clear evidence of carcinogenic
activity in both sexes of both species.
These results were similar to those ob-
served for all the other substituted
anthraquinones studied and may permit
judgments of the general carcinogenic
nature ofthis class ofcompounds.
In a different set of studies, the NTP
evaluated three mouse strains for sensitivi-
ty to the action of known initiators, pro-
moters, and complete carcinogens.
B6C3F1 mice, the strain most frequently
used in NTP studies, were compared with
two strains of mice known to be sensitive
to carcinogens, the SENCAR and Swiss
(CD-1), in a series of one-year skin paint
studies. All three strains ofmice developed
skin tumors when given a variety of skin
carcinogens, with SENCAR mice exhibit-
ing the greatest sensitivity (earlier onset and
increased multiplicity). Although B6C3F1
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